JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ: MIRM ) with a Overweight and raises the price target from $115 to $125.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.